Fatty Acids Side Chains
Fatty acid side chains are known to improve patient compliance by to prolonging the half-life of Glucagon-like peptide-1 (GLP-1) receptor agonists used in the treatment of type II diabetes and obesity. Several drug entities such as tirzepatide, somapacitan, or semaglutide, are modified with fatty acid side-chains in order to increase their affinity for albumin.
| Product Name | Purity | CAS No. |
| tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu | ≥98% | 1118767-16-0 |
| Ste-Glu-AEEA-AEEA-OSU | ≥90% | 1169630-40-3 |
| tBuO-Ste-Glu(AEEA-AEEA-OSU)-OtBu | ≥95% | 1118767-15-9 |
| Fmoc-Lys(tBuO-Ste-Glu(AEEA-AEEA)-OtBu)-OH | ≥98% | 1662688-20-1 |
| tBuO-ICO-Glu(AEEA-AEEA-OH)-OtBu | ≥98% | 1188328-37-1 |
| ICO-Glu-AEEA-AEEA-OSU | ≥90% | 1188328-38-2 |
| tBuO-ICO-Glu(AEEA-AEEA-OSU)-OtBu | ≥95% | 1118767-17-1 |
| Fmoc-Lys(tBuO-ICO-Glu(AEEA-AEEA)-OtBu)-OH | ≥98% | 2460751-66-8 |
